بدائل البحث:
significant barrier » significant burden (توسيع البحث)
barrier biased » carrier based (توسيع البحث)
ns decrease » _ decrease (توسيع البحث), a decrease (توسيع البحث), we decrease (توسيع البحث)
nn decrease » _ decrease (توسيع البحث), a decrease (توسيع البحث), mean decrease (توسيع البحث)
significant barrier » significant burden (توسيع البحث)
barrier biased » carrier based (توسيع البحث)
ns decrease » _ decrease (توسيع البحث), a decrease (توسيع البحث), we decrease (توسيع البحث)
nn decrease » _ decrease (توسيع البحث), a decrease (توسيع البحث), mean decrease (توسيع البحث)
-
121
-
122
-
123
-
124
HFD decreases ITM and alters metabolic homeostasis.
منشور في 2025"…Two-way ANOVA, n.s., not significant, ** p < 0.01). <b>(F)</b> Long-term memory (LTM) was significantly decreased in the HFD group. …"
-
125
-
126
-
127
B2 decreases glycolytic intermediates in cells.
منشور في 2025"…Other abbreviations: HGA, DL-hydroxyglutaric acid; PEP, phosphoenolpyruvic acid; 3-PGA, 3-phosphoglyceric acid; G3P; glyceraldehyde 3-phosphate; Data (n = 5) are shown as mean±SD. Not significant (ns): **<i>P</i> ≤ 0.01, ****<i>P</i> ≤ 0.0001by one-way ANOVA with multiple comparison of the mean of each test group to the mean of the vehicle control. …"
-
128
Downregulation of DOM decreases the abundance of PER and TIM.
منشور في 2019"…Error bars represent ± SEM; n.s., non significant,*<i>P</i> < 0.05,**p < 0.01, ***p < 0.001, one-way ANOVA. …"
-
129
-
130
Depletion of ERp29 decreases cellular Proinsulin.
منشور في 2020"…(D, E) Transiently transfected Min-6 cells were lysed and analyzed by ELISA. Proinsulin levels decreased when transfected with ERp29-targeting siRNA as compared to controls (D, p = 0.0309), but Insulin content did not significantly change (E, p = ns).…"
-
131
-
132
Regenerating axons are increased by ATRA and decreased by clodronate.
منشور في 2021"…Numbers of animals are shown. Asterisks or “ns” above each column indicate the significance when compared to PBS control (row 1, gray), ATRA (row 2, green), or clodronate (row 3, red) with ANOVA and <i>post-hoc</i> Tukey tests. …"
-
133
-
134
GSK2818713, a Novel Biphenylene Scaffold-Based Hepatitis C NS5A Replication Complex Inhibitor with Broad Genotype Coverage
منشور في 2020"…The discovery of GSK2818713 (<b>13</b>), a nonstructural protein 5A (NS5A) HCV inhibitor characterized by a significantly improved genotype coverage relative to first-generation NS5A inhibitor daclatasvir (DCV), is detailed herein. …"
-
135
-
136
-
137
-
138
-
139
-
140